A novel approach for early diagnosis and personalized therapy to pancreatic cancer by metabolic profiling

我们对两个吉西他滨耐药的胰腺癌细胞及其亲本进行了代谢谱分析，然后检测了它们之间30%的代谢谱差异。此外，我们还对12个冰冻组织芯片中的切除标本进行了基质辅助激光解吸/电离成像质谱仪。在每个切片上识别和定位了40多种代谢物，有趣的是，一些代谢物在正常组织和肿瘤组织中显示出不同的分布。我们将继续研究这些已鉴定的代谢物，以期实现早期诊断和个体化用药。

We performed metabolic profiling analysis with two Gemcitabine resistant pancreatic cancer cell lines and their parent strains by Liquid Chromatography - tandem Mass Spectrometry , then detected variance in 30 % metabolic profiling between them. Furthermore, we also performed matrix-assisted laser desorption/ionization imaging mass spectrometry with 12 resected specimens which arrayed in frozen tissue microarray. More than 40 kinds of metabolites were identified and mapped on the each section, and interestingly some of metabolites showed different distributions between normal and tumor tissue. We will investigate these identified metabolites continuously for possibility of early diagnosis and personalized medicine.